Please try another search
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Name | Age | Since | Title |
---|---|---|---|
George S. Golumbeski | 66 | 2018 | Independent Chairman of the Board |
Kurt Schalper | - | - | Member of Advisory Board |
Drew Mark Pardoll | - | 2020 | Member of Advisory Board |
Neil W. Gibson | 67 | 2016 | Independent Director |
Carrie Brownstein | 53 | 2021 | Independent Director |
Ignacio Melero | - | - | Member of Advisory Board |
Helen Marie Boudreau | 57 | 2020 | Independent Director |
Tyler Brous | 40 | 2016 | Lead Independent Director |
Johann de Bono | - | - | Member of Advisory Board |
Aurelien Marabelle | - | 2020 | Member of Advisory Board |
Michael Lee | 43 | 2020 | Independent Director |
Clay B. Siegall | 63 | 2024 | Independent Director |
Kate Sasser | 47 | 2024 | Independent Director |
Taylor H. Schreiber | 44 | 2016 | Co-Founder, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review